{"type":"trials","record":{"id":29364,"source_id":"clinicaltrials-gov","external_id":"NCT04332302","title":"Power Strength Training in Type 2 Diabetic Mellitus Older Adults","brief_summary":"Diabetes is a disease with a high impact in the population older than 65 years old. Some indications suggest that diabetes in the old age aggravate the negative effects of ageing, as the loss of muscle mass and strength, bringing the patients to a situation of vulnerability and elevated risk of disability and death known as \"frailty syndrome\". Recently, scientists have observed that if older population train with musculation machines emphasising the muscular power, it is possible to have an impact on a disminution of frailty and restoring the physical functionality. This project deeps in the physiological and molecular mechanisms that underlie to improvements in the frail diabetic patients.","overall_status":"Unknown","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Technical University of Madrid","enrollment":41,"countries":["Spain"],"start_date":"2020-01-15","completion_date":"2021-12-21","last_update_date":"2020-10-19","source_url":"https://clinicaltrials.gov/study/NCT04332302","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:00:07.808+00:00","metadata":{"sex":"ALL","acronym":"DIAPOW","age_range":"65 Years","comparator":"Control group","organization":"Technical University of Madrid","interventions":["Power resistance training"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from Baseline Glycosylated Hemoglobin (Hemoglobin A1c) at 12 weeks — 0 and 12 weeks.","Change from Baseline Homeostasis Model Assessment - Beta cells (HOMA2-B) at 12 weeks — 0 and 12 weeks.","Change from Baseline Homeostasis Model Assessment - Insuline Resistance (HOMA2-IR) at 12 weeks — 0 and 12 weeks.","Change from Baseline Fried frailty score at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Functional capacity at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Disability at 6 and 12 weeks — 0, 6 and 12 weeks.","Functional mobility at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Muscular power at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Levels of strength at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Bone Mineral Density at 12 weeks — 0 and 12 weeks.","Change from Baseline Pigment Epitelium Derived Factor (PEDF) at 12 weeks — 0 and 12 weeks.","Genotyping of TCF7L2 (rs7903146) — 0 week.","Genotyping of TM6SF2 (rs10401969) — 0 week.","Genotyping of HLA (rs2854275) — 0 week.","Change from Baseline Body Mass Index at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Waist circumference at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Blood pressure (systolic and diastolic) at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Concentration of Triglycerides at 12 weeks — 0 and 12 weeks.","Change from Baseline Concentration of Total Cholesterol at 12 weeks — 0 and 12 weeks.","Change from Baseline Concentration of HDL Cholesterol at 12 weeks — 0 and 12 weeks."],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · SINGLE","source_has_results":false},"controlled_terms":["Diabetes Mellitus, Type 2","Frailty","Power resistance training"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: strength training.","quality_checked_at":"2026-09-25T06:00:15.557161+00:00","duplicate_cluster_key":"id:nct04332302","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-01-15 to 2021-12-21","comparator":"Control group","confidence":"structured-source","population":"ALL · 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:00:07.876Z","intervention":["Power resistance training"],"participants":41,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from Baseline Glycosylated Hemoglobin (Hemoglobin A1c) at 12 weeks — 0 and 12 weeks.","Change from Baseline Homeostasis Model Assessment - Beta cells (HOMA2-B) at 12 weeks — 0 and 12 weeks.","Change from Baseline Homeostasis Model Assessment - Insuline Resistance (HOMA2-IR) at 12 weeks — 0 and 12 weeks.","Change from Baseline Fried frailty score at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Functional capacity at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Disability at 6 and 12 weeks — 0, 6 and 12 weeks.","Functional mobility at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Muscular power at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Levels of strength at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Bone Mineral Density at 12 weeks — 0 and 12 weeks.","Change from Baseline Pigment Epitelium Derived Factor (PEDF) at 12 weeks — 0 and 12 weeks.","Genotyping of TCF7L2 (rs7903146) — 0 week.","Genotyping of TM6SF2 (rs10401969) — 0 week.","Genotyping of HLA (rs2854275) — 0 week.","Change from Baseline Body Mass Index at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Waist circumference at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Blood pressure (systolic and diastolic) at 6 and 12 weeks — 0, 6 and 12 weeks.","Change from Baseline Concentration of Triglycerides at 12 weeks — 0 and 12 weeks.","Change from Baseline Concentration of Total Cholesterol at 12 weeks — 0 and 12 weeks.","Change from Baseline Concentration of HDL Cholesterol at 12 weeks — 0 and 12 weeks."],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"resistance-training","is_published":true,"match_reasons":["Title contains controlled term: strength training.","Source terminology contains: resistance training.","Title supplies longevity context: older adult.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Resistance training","slug":"resistance-training"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29364","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}